ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO) Files An 8-K Other Events
Item 8.01. Other Events.
On October 2, 2019, Organovo Holdings, Inc. (the “Company”) issued a press release (i) acknowledging receipt of a proposal to acquire ownership control of the Company and (ii) reiterating the Company’s commitment to the previously disclosed strategic alternatives process.
A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
ORGANOVO HOLDINGS, INC. Exhibit
EX-99.1 2 onvo-ex991_6.htm EX-99.1 onvo-ex991_6.htm EXHIBIT 99.1 Contact: Investor Relations Organovo Holdings,…
To view the full exhibit click here
About ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO)
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
